13 – 16/02/2025
GRAND HOTEL PALACE, Thessaloniki.
IASIS PHARMA participated in the “14th Panhellenic Conference on Alzheimer’s Disease & 6th Mediterranean Conference on Neurodegenerative Diseases” actively expressing its interest in the specialty of Neurology.
The hybrid 14th Panhellenic Conference on Alzheimer’s Disease was held on 13 – 16 February 2025 in Thessaloniki, at the Grand Hotel Palace.
At least 400 participants participated in the conference.
IASIS PHARMA actively participated by promoting Referan®, with the active substance Aniracetam as an original pharmaceutical product with an indication in MCI: Mild Cognitive Impairment.
IASIS PHARMA also participated with a satellite lecture on the topic of “Modern treatment of Mild Cognitive Disorder (MCD)” with Speaker Ms. Magda Tsolaki, Neurologist-Psychiatrist, Emeritus Professor of Aristotle University of Thessaloniki and President of the Panhellenic Alzheimer’s Disease Federation, where she emphasized the importance and effectiveness of Referan/Aniracetam in the treatment of MCI.
Referan®/ Aniracetam is available for monthly treatment in packages:
- 30 sachets (sachets with single-dose granules for drinking liquid of 1500mg)
- 60 f.c. tablets (film-coated tablets of 750mg)
